2010
DOI: 10.1007/s00296-010-1366-9
|View full text |Cite
|
Sign up to set email alerts
|

Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

Abstract: The aim of this study was to prospectively evaluate the efficacy and safety of tacrolimus (TAC) in various manifestations of systemic lupus erythematosus (SLE) patients in daily clinical practice. Each of the 21 TAC-treated patients with SLE in our care over 2 years was enrolled in this open-label trial. Patients were administered TAC at a dosage of 1-6 mg once daily, followed up for 24 weeks. Efficacy and safety were evaluated utilizing clinical and laboratory findings. As treatment targets, TAC was preferent… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
21
0

Year Published

2010
2010
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 29 publications
(22 citation statements)
references
References 36 publications
1
21
0
Order By: Relevance
“…Two studies assessed the efficacy and/or safety of TAC in the treatment of nonrenal manifestations of SLE; both were cohort studies () that included 31 patients. In the open‐label prospective 24‐week study by Suzuki et al (), 21 patients with mild active SLE treated with oral TAC (1–6 mg/day) were studied. The mean SLEDAI score decreased significantly at 24 weeks ( P < 0.01).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Two studies assessed the efficacy and/or safety of TAC in the treatment of nonrenal manifestations of SLE; both were cohort studies () that included 31 patients. In the open‐label prospective 24‐week study by Suzuki et al (), 21 patients with mild active SLE treated with oral TAC (1–6 mg/day) were studied. The mean SLEDAI score decreased significantly at 24 weeks ( P < 0.01).…”
Section: Resultsmentioning
confidence: 99%
“…There is very little evidence for the use of calcineurin inhibitors because CSA was assessed in 2 small unblinded, non–placebo‐controlled RCTs () and TAC was assessed in 2 small low‐quality non‐RCTs (). The withdrawal rate was high for both drugs; therefore, concern about their side effects is a barrier to generalizing their use.…”
Section: Discussionmentioning
confidence: 99%
“…Missing clinical data (from 3 patients at 24 months and 5 patients at 36 months of treatment) were substituted using the last observation carried forward method [27]. Sustained long-term favorable changes in each clinical parameter were observed at 24 and 36 months and at the last on-treatment observation point, and the serum creatinine levels remained unchanged.…”
Section: Resultsmentioning
confidence: 99%
“…Tacrolimus can therefore be considered both effective and safe for treating mild manifestations of LE, including skin dermatosis, in systemic LE patients. However, for severe active conditions, its efficacy is limited at current dose settings and usage [56]. …”
Section: Resultsmentioning
confidence: 99%